New COX-2 Inhibitors.
10.3904/kjm.2016.91.3.350
- Author:
Dam KIM
1
;
Yoon Kyoung SUNG
Author Information
1. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. sungyk@hanyang.ac.kr
- Publication Type:Brief Communication
- Keywords:
Anti-inflammatory agents, Non-steroidal;
Cyclooxygenase inhibitors;
Safety
- MeSH:
Anti-Inflammatory Agents, Non-Steroidal;
Cyclooxygenase 2 Inhibitors*;
Cyclooxygenase Inhibitors;
Humans;
Incidence;
Inflammation;
Korea;
Osteoarthritis;
Prostaglandin-Endoperoxide Synthases
- From:Korean Journal of Medicine
2016;91(3):250-256
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammation. There are two kinds of NSAID classified according to the selectivity of COX-2 inhibition: non-selective NSAIDs and cyclooxygenase (COX)-2 inhibitors. Non-selective NSAIDs have a high incidence of gastrointestinal and bleeding-associated adverse events, while COX-2 inhibitors are safer in terms of these events. However, COX-2 inhibitors are thought to cause increased cardiovascular events. The COX-2 inhibitors rofecoxib and valdecoxib were withdrawn from the market over safety concerns. Three COX-2 inhibitors are now available in South Korea after the recent approval of etoricoxib and polmacoxib for osteoarthritis patients. After reviewing the history of and recent studies about the safety of COX-2 inhibitors, physicians should find new uses for old drugs.
